The present invention relates to an oral composition having an enhanced solubility of an alkyl galactoside while holding an inhibiting effect on coaggregation of the alkyl galactoside well. The present invention provides an oral composition comprising the following components: (A) 0.001 mass% or more and 1 mass% or less of a compound represented by the following formula (I): wherein R is an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G is a galactose residue, E is a hydrogen atom or a methyl group, m is an integer of 0 to 200, and n is an integer of 1 to 30 (B) 0.001 mass% or more and 0.1 mass% or less of a cationic bactericide and (C) 35 mass% or more of water.
